EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC)

Phase 1 Completed 12 enrolled Baylor College of Medicine Center for Cell and Gene Therapy, Baylor College of Medicine · collab The Methodist Hospital Research Institute · collab

NaSingle-groupOpen-labelTreatment

Summary

To determine the safety of the combination of CD45 monoclonal antibody (Mab) followed by intravenous injection of EBV specific CTL in patients with nasopharyngeal cancer. To compare the expansion, persistence and anti-tumor effects of the EBV specific CTL given after CD45 Mab administration with that observed in our first study. To obtain preliminary information on the safety and response to an extended dosage regimen of EBV-specific CTL in patients, who have stable disease or a partial response after the initial dose of EBV-specific CTL.

Timeline

Start: 2003-09
Primary completion: 2007-01
Completion: 2007-04

Publications

Louis CU, Straathof K, Bollard CM, Gerken C, Huls MH, Gresik MV, Wu MF, Weiss HL, Gee AP, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood. 2009 Mar 12;113(11):2442-50. doi: 10.1182/blood-2008-05-157222. Epub 2008 Oct 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Anti-CD45	Protein / enzyme biologic	400 ug/kg	Intravenous
Subject	EBV-specific CTL	Cell therapy	2e+07 unknown	Intravenous
Subject	EBV-specific CTL	Cell therapy	5e+07 unknown	Intravenous
Subject	EBV-specific CTL	Cell therapy	1e+08 unknown	Intravenous

EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC)

Summary

Timeline

Publications

Drugs

Indications